Korro Bio, Inc. (KRRO)
| Previous close | 54.01 |
| Open | 51.42 |
| Bid | 49.96 x 100 |
| Ask | 53.48 x 100 |
| Day's range | 51.42 - 53.34 |
| 52-week range | 9.15 - 97.91 |
| Volume | |
| Avg. volume | 34,657 |
| Market cap | 482.179M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 130.00 |
GlobeNewswireKorro Announces $70 Million Private Placement
Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Proceeds fund interim readout in the second half of 2025 and FIH study completion in 2026 for KRRO-110 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE)
- GlobeNewswire
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present, and meet investors regarding progress of KRRO-110, Korro’s best-in-class candidate for AATD, at the following upcoming investor conferences: 23rd Annual Needham Healthcare ConferenceFormat: PresentationDate an
- GlobeNewswire
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Demonstrated the versatility of Korro’s RNA editing platform by generating de-novo protein variants via multiple targets in non-human primates (NHPs) Demonstrated greater than 50% editing using GalNAc conjugates in the liver with subcutaneous administration in a preclinical mouse modelEnded 2023 with a strong balance sheet of $166 million of
